Biodesix announced its intent to acquire the Oncimmune Holdings Group’s laboratory and (IPN) malignancy test in the US
Biodesix to acquire Oncimmune’s laboratory and incidental pulmonary nodule malignancy test in the U.S.
Immodulon will utilize biomarkers identified by Biodesix' machine learning platform, aiming to accelerate the clinical development of its pancreatic treatment.
Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex.
Biodesix, has recently presented new data demonstrating that the company’s VeriStrat test is predictive of outcomes for patients with non-small cell lung cancer.
A new collaboration could be key in the early detection of lung cancer.
Data suggest that a blood-based test from Biodesix has the potential to detect pretreatment risk of anti-PD-1 immunotherapy resistance among NSCLC patients
Biodesix Partners with MRM for mass spec proteomics development
Test Predicts Primary Resistance to Anti-PD-1 Immunotherapy against Non-Small Cell Lung Cancer.
Dr. Skibo discusses how ddPCR-based liquid biopsy could be the solution to treatment delays due to receiving genetic information late